ArticleZhongguo fei ai za zhi = Chinese journal of lung cancer2013
[Expression and related factors of Galectin-3 in non-small cell lung cancer].
Article in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 5 citations in OpenAlex.
- The Expression of Snail, Galectin-3, and IGF1R in the Differential Diagnosis of Benign and Malignant Pheochromocytoma and Paraganglioma.BioMed research international · 2020Article
- Galectin-3 activates TLR4/NF-κB signaling to promote lung adenocarcinoma cell proliferation through activating lncRNA-NEAT1 expression.BMC cancer · 2018Article
- Prognostic role of galectin-3 expression in patients with solid tumors: a meta-analysis of 36 eligible studies.Cancer cell international · 2018Article
- Mer receptor tyrosine kinase is frequently overexpressed in human non-small cell lung cancer, confirming resistance to erlotinib.Oncotarget · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveGalectin-3 is involved in many physical and pathologic process, and is closely correlated with tumorigenesis, development and metastasis. The aim of this study is to investigate the gene expression and significance of Galectin-3 in normal lung tissue and non-small cell lung cancer (NSCLC) tissue.
methodsGene expression was examined using the immunohistochemical S-P method in 62 NSCLC cases and in 17 cases with normal lung tissue. RT-PCR verified the expression of Galectin-3 at the transcriptional level.
resultsThe expression rate of Galectin-3 in NSCLC tissue was 83.8% (52/62), which was significantly higher than that in normal lung tissue (P<0.01). Galectin-3 expression was not correlated with sex (χ²=0.113, P>0.05), age (χ²=0.220, P>0.05), and histological type (χ²=0.012, P>0.05), but was negatively correlated with pathological differentiation (r=-0.292, P<0.05) and positively correlated with the clinical stage (r=0.336, P<0.05) in NSCLC tissue. RT-PCR results showed that the expression level of Galectin-3 in NSCLC tissue was significantly higher than in normal lung tissue.
conclusionsGalectin-3 may be useful in lung cancer diagnosis and may increase diagnosis rate when combined with other lung cancer markers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.